Premium
Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab
Author(s) -
Low Zhi Mei,
Mar Adrian
Publication year - 2018
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.12744
Subject(s) - pyoderma gangrenosum , ustekinumab , medicine , dermatology , interleukin 23 , interleukin , disease , cytokine , infliximab
An increased expression of interleukin‐23 has been observed in patients with pyoderma gangrenosum, leading to the use of ustekinumab as a therapeutic option. We report the successful use of ustekinumab in three patients with treatment‐resistant pyoderma gangrenosum of varying clinical presentations.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom